安博维对轻、中度原发性高血压病患者左心室舒张功能影响(1)
 |
| 第1页 |
参见附件(2815KB，3页)。
[摘要]目的 探讨厄贝沙坦(安博维)治疗轻、中度原发性高血压病(EH)患者左心室舒张功能的疗效。方法 将89例轻、中度EH患者随机分为厄贝沙坦组和贝那普利组，于用药前和服药6个月后，分别检测24 h动态血压，心脏多普勒超声、血浆脑钠素(BNP)。结果 治疗6个月后，各项血压指标较治疗前有显著下降，差异均有统计学意义(P<0.05)；两组心脏超声各项指标较治疗前均有改善，且LVPWD、IVSD 和LVMI厄贝沙坦组显著低于贝那普利组(P<0.05)；两组患者治疗后血浆BNP水平较治疗前均有下降，而厄贝沙坦组下降得更显著，两组比较差异有统计学意义(P<0.05)。结论 安博维能够有效降低血压，改善轻、中度EH患者左心室舒张功能。
[关键词] 安博维；原发性高血压；左心室舒张；血浆脑钠素
[中图分类号] R544.1 [文献标识码] A [文章编号]1673-9701(2011)22-48-03
Effect of Irbesartan on the Left Ventricular Diastolic Function in Patients with Mild and Moderate Essential Hypertension
WANG Dong1 GU Fangfang2
1.Department of Emergency， Huzhou Municipal Central Hospital in Zhejiang Province， Huzhou 313000， China；2. Department of Cardiology，Huzhou Municipal Central Hospital in Zhejiang Province， Huzhou 313000， China
[Abstract] Objective To study the effect of Irbesartan on the treatment of the left ventricular diastolic function in patients with mild and medium degree essential hypertension. Methods Eighty-nine patients with mild and medium degree essential hypertension were randomly divided into Irbesartan group and Benazepril group and 24h average blood pressure， doppler echocardiography， the lever of brain natriuretic peptide were measured before receiving therapy and after treatment for 6 months. Results Blood pressure and indicators of doppler echocardiography were all significantly improved in both groups after treatment (P<0.05)， and the levels of LVPWD， IVSD and LVMI decreased more apparently in Benazepril group(P<0.05). The levels of BNP were significant decreased in both groups after treatment， but more apparently in Irbesartan group(P<0.05). Conclusion Irbesartan can reduce blood pressure and improve the left ventricular diastolic function in patients with mild and medium degree essential hypertension.
[Key words] Irbesartan； Essential hypertension； Left ventricular diastolic； Brain natriuretic peptide(BNP)
高血压心力衰竭的早期表现即为心室舒张功能障碍，对其进行早期诊断和临床干预有重要意义。研究表明，原发性高血压(EH)伴心功能不全可导致血浆脑钠素(BNP)水平显著升高，而血管紧张素受体Ⅱ拮抗剂(ARB)对EH患者的心脏具有保护作用[1，2]。厄贝沙坦(安博维)作为新一代高选择性ARB，可与血管紧张素Ⅱ(AngⅡ)-1型受体(AT1) 特异性地结合，完全抑制并阻断AngⅡ引起的血压升高。本研究旨在探讨安博维对EH患者左心室舒张功能的影响及血浆BNP水平改变的意义。
1 资料与方法
1 ......
您现在查看是摘要介绍页，详见PDF附件(2815KB，3页)。